Core Viewpoint - The Hang Seng Technology ETF (520570) has seen significant inflows and positive performance, indicating a recovery in the Hong Kong stock market, particularly in the technology sector, following recent corrections [1][2]. Group 1: Market Performance - As of February 9, 2026, the Hang Seng Technology ETF (520570) rose by 1.14% with a turnover of 2.76%, amounting to 75.36 million yuan [1]. - The Hang Seng Technology Index components, including Huahong Semiconductor, JD Health, and SMIC, experienced gains of 4.79%, 4.31%, and 3.48% respectively [1]. - Southbound funds have consistently flowed into the Hong Kong stock market, with net inflows recorded for seven consecutive trading days as of February 6, 2026 [1]. Group 2: Fund Inflows - Southbound funds achieved a net buying amount exceeding 56 billion yuan in the week from February 2 to 6, marking the highest weekly inflow since late September of the previous year [1]. - On February 6, the net buying amount reached a recent high of 22.206 billion yuan, with the last three trading days seeing net purchases exceeding 10 billion yuan each [1]. Group 3: Investment Outlook - China Galaxy Securities suggests that the valuation attractiveness of Hong Kong stocks has increased following recent corrections, with expectations of a rebound in the market around the Chinese New Year [2]. - The technology sector remains a key focus for medium to long-term investments, with reduced valuation pressure and potential for recovery [2]. - The Hang Seng Technology Index includes the top 30 Hong Kong-listed companies highly related to technology themes, representing major players in sectors such as internet, fintech, cloud computing, e-commerce, and digital business [2].

Core Insights - The report emphasizes the potential of the AI industry and high-growth segments like gaming, suggesting that recent market corrections present better entry opportunities [10][13][17]. E-commerce Sector - The e-commerce sector remains constrained by market sentiment and macroeconomic weakness, with low growth and profit expectations for Q4 [10][13]. - Alibaba's Qianwen App launched a 3 billion yuan subsidy campaign, achieving over 10 million orders in 9 hours, indicating a competitive AI agent market [10][13]. - Meituan's acquisition of Dingdong Maicai for approximately 50 billion yuan reflects a strategic move to strengthen its position in instant retail [10][14]. Social Entertainment Media - Bilibili and Tencent show strong advertising momentum, with Tencent's gaming fundamentals improving, particularly with the anticipated success of "Delta Action" [10][13][15]. - Bilibili's self-developed game "Shining! Luming" is set to release new products gradually in 2026, enhancing its product pipeline [10][15]. Internet Healthcare - JD Health and Alibaba Health leverage their leading platform advantages to deepen collaborations with upstream pharmaceutical manufacturers, resulting in strong revenue and profit growth [10][15]. Short Video Sector - Kuaishou's main business remains stable, with its AI technology leading in commercialization, optimizing user engagement and conversion data [10][15]. Trendy Play + IP Sector - Pop Mart announced the establishment of its European headquarters in London, planning to open 27 new stores in Europe, which will create over 150 jobs [10][15]. Long Video Sector - Multiple platforms are releasing quality series, with a focus on investment opportunities in iQIYI and Mango Excellent Media, which are currently at low valuations [10][15]. Music Streaming - Tencent Music and NetEase Cloud Music reported stable performance, although concerns about competition have led to valuation adjustments [10][16]. Gaming Sector - The gaming sector is expected to maintain its performance driven by fundamentals, with continued recommendations for leading companies like Tencent and NetEase [10][17]. - New game reserves from companies like Perfect World and 37 Interactive Entertainment are anticipated to boost performance through product launches [10][17]. Advertising Sector - The adjustment of Shuhua will not affect the operational trends of Focus Media, with increased advertising investments expected from internet advertisers in 2026 [10][18]. AI Sector - AI is driving accelerated growth in overseas CSP cloud revenues and orders, with a new round of AI model and product iterations emerging [10][19]. - Recommendations include focusing on major cloud players like Google and Amazon, as well as domestic giants like Alibaba and Tencent [10][19].

Group 1 - Southbound funds increased their holdings in Alibaba Health (00241.HK) by 4.238 million shares on February 6 [1] - Over the past 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 26.959 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, with a total net increase of 181 million shares [1] Group 2 - As of now, southbound funds hold 1.945 billion shares of Alibaba Health, accounting for 12.02% of the company's total issued ordinary shares [1] - Alibaba Health Information Technology Co., Ltd. provides industrial internet solutions for the medical and pharmaceutical industry and is Alibaba Group's flagship platform in the health sector [1] - The company primarily engages in the sales of pharmaceutical health products, operates a pharmaceutical e-commerce platform, and offers consumer medical services, utilizing cloud computing and big data technologies for traceability and digital healthcare [1]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

腾讯控股 547.500 -1.970% 194.72亿 每经记者｜杜恒峰 每经编辑｜段炼 记者|杜恒峰 编辑|段炼 易启江 校对|金冥羽 2月6日，港股三大指数全线下跌，恒生指数跌1.21%，国企指数跌0.681%，恒生科技指数跌1.109%。 科网股齐跌，阿里巴巴跌近3%，美团、金山软件、京东健康、百度集团、网易等跌超2%，腾讯控股跌近2%，京东集团、阿里健康、携程集团等跌超 1%。 汽车股上涨，蔚来涨近7%，零跑汽车涨超5%，理想汽车涨超3%。 92.300 +1.151% 26.55亿 蔚来5日发布业绩盈利预告称，基于对公司未经审计合并管理账目及董事会目前可得资料的初步评估，预计公司2025年第四季度将实现经调整经营利润 （非公认会计准则，剔除股权激励费用后的经营利润）约7亿元至12亿元，这是蔚来成立11年来首次实现单季度经调整经营盈利。按公认会计准则计量， 预计同期将实现经营利润约2亿元至7亿元。 后市展望： 00700 百度官宣 50亿美元回购计划!腾讯、小米已近百亿港元扫货 阿里巴巴－W 09988 千问崩了,阿里巴巴跌超3% 小米集团－W 35.180 +0.745% 47.17亿 01810 ...

Group 1 - The core point of the article highlights a decline in Hong Kong's tech stocks, with notable companies such as Bilibili, Tencent Music, and Kuaishou experiencing drops of over 2% [1] - Alibaba, Tencent Holdings, BOSS Zhipin, Alibaba Health, and NetEase also saw declines, indicating a broader trend in the tech sector [1] Group 2 - The article mentions specific stock performance, indicating that multiple key players in the tech industry are facing downward pressure [1]

2月5日，恒生指数低开0.82%，恒生科技指数跌1.31%。 百度逆势涨超2%，董事会授权一项总金额不超过50亿美元的股票回购计划。 编辑｜钉钉 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 恒生指数 | 26627.95 | -219.37 | -0.82% | | 恒生科技 | 5295.89 | -70.55 | -1.31% | | 恒生生物科技 | 14995.29 | -160.91 | -1.06% | | 恒生中国企业指数 | 8978.46 | -69.92 | -0.77% | | 恒生综合指数 | 4073.68 | -33.61 | -0.82% | 科网股延续跌势，哔哩哔哩跌逾4%，腾讯音乐、华虹半导体跌逾3%，阿里巴巴、快手、中芯国际、美 团等跌逾2%。 | 名称 | 现价 | 涨跌 | 涨跌幅 - | | --- | --- | --- | --- | | 哔哩哔哩-W | 233.600 | -10.000 | -4.11% | | 腾讯音乐-SW | 62.200 | -2.300 | -3.57% | | 金蝶国际 | ...

| 名称 | 现价 | | 涨跌幅 - | | --- | --- | --- | --- | | 哔哩哔哩-W | 233.600 -10.000 | | -4.11% | | 腾讯音乐-SW | 62.200 | -2.300 | -3.57% | | 金蝶国际 | 10.710 | -0.350 | -3.16% | | 华虹半导体 | 99.300 | -3.100 | -3.03% | | 『国語学-W | 155.500 | -4.000 | -2.51% | | 快手-W | 71.500 | -1.650 | -2.26% | | 中村国际 | 67.200 | -1.550 | -2.25% | | 美团-W | 90.200 | -1.950 | -2.12% | | 小鹏汽车-W | 65.500 | -1.050 | -1.58% | | 京东集团-SW | 106.300 | -1.600 | -1.48% | | 腾讯控股 | 550.000 | -8.000 | -1.43% | | 金山软件 | 27.300 | -0.380 | -1.37% | | 同程旅行 | 22.00 ...

定焦One（dingjiaoone）原创 见习作者 | 雷晶 营收、净利润 分业务来看，其中，被冠以"AI"标签、与"健共体"模式绑定的医疗服务（含健康管理会员服务、云药 房、增值服务），占比也从2022年的45.9%，增长至2025年上半年的92.2%，尤其是健康管理会员服 务，已成为绝对的收入支柱。 这家公司是微医。它最早成立于2004年，前身是"挂号网"，2015年更名为微医，并在同年发起成立了中 国首家互联网医院。比起今天高调入局AI医疗的新玩家们，微医算得上是互联网医疗最早的一批探索 者。 然而，这家公司的上市之路可谓是一波三折。2025年9月底，它再次港交所递交了上市申请。这已经是 它自2021年4月以来，第三次冲刺IPO。 在这期间，它的定位也在变。2021年4月，微医将自己定义为"中国最大的数字医疗服务平台"。2024年 12月，变成了"中国最大的AI医疗健康解决方案提供商"。到了2025年9月，进一步强调AI属性。 标签在换，但资本市场的核心问题没变：这家公司到底赚不赚钱？ 从营收看，微医确实在增长。招股书显示，2022年至2024年，其收入从13.7亿元增到至55.0亿元，年均 复合增长率 ...

Core Viewpoint - The rumors regarding a 32% tax rate on the internet industry are unfounded and lack a basis in the current tax system, which does not allow for such arbitrary adjustments [3][8]. Group 1: Tax Rumors and Market Impact - Since February 2, rumors about increased taxes in the internet sector have caused significant volatility in the tech sector, despite the illogical nature of these claims [1]. - Previous instances of tax rumors have led to market downturns, such as the 2021 speculation about the cancellation of a 10% preferential tax rate for internet companies [5][6]. Group 2: Tax Rate Structure - The current VAT rates in China are 6%, 9%, and 13%, with no provision for a 32% rate, which is incompatible with the existing tax framework [3][4]. - The nature of the internet gaming industry, characterized by high human resource costs and low deductibility of input taxes, justifies a lower VAT rate [3][4]. Group 3: Policy Stability and Economic Growth - The stability of tax laws is crucial for economic foundations, and any changes to tax rates require extensive negotiation and cannot be made arbitrarily [8]. - The overarching goal of China's macroeconomic policy is to maintain growth, which necessitates consistent policies that support the digital economy and technology sectors [8][11]. Group 4: Role of Technology in Economic Development - The internet and gaming sectors are increasingly recognized as vital components of technological advancement, contributing to various fields, including military training and AI development [9][11]. - Continuous investment in AI and other cutting-edge technologies by internet companies indicates that significant policy adjustments are unlikely to occur suddenly [11].